A previous study showed that inhibition of sodium/glucose cotransporter 1 (SGLT1) sensitized prostate cancer cells to EGFR inhibitors (gefitinib and erlotinib) (Wright et al., 2011), although the precise mechanisms have not been elucidated. The gene discussed is SLC5A1; the disease is prostate cancer.